作者
Sarah EJ Chambers, Varun Pathak, Edoardo Pedrini, Lou Soret, Nicolas Gendron, Coralie L Guerin, Alan W Stitt, David M Smadja, Reinhold J Medina
发表日期
2021/11/1
来源
Stem Cells Translational Medicine
卷号
10
期号
S2
页码范围
S54-S61
出版商
Oxford University Press
简介
Ischemic vascular disease is a major cause of mortality and morbidity worldwide, and regeneration of blood vessels in perfusion-deficient tissues is a worthwhile therapeutic goal. The idea of delivering endothelial stem/progenitor cells to repair damaged vasculature, reperfuse hypoxic tissue, prevent cell death, and consequently diminish tissue inflammation and fibrosis has a strong scientific basis and clinical value. Various labs have proposed endothelial stem/progenitor cell candidates. This has created confusion, as there are profound differences between these cell definitions based on isolation methodology, characterization, and reparative biology. Here, a stricter definition based on stem cell biology principles is proposed. Although preclinical studies have often been promising, results from clinical trials have been highly contradictory and served to highlight multiple challenges associated with …
引用总数
学术搜索中的文章
SEJ Chambers, V Pathak, E Pedrini, L Soret… - Stem Cells Translational Medicine, 2021